Compugen (NASDAQ:CGEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, July 24th.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Other analysts have also issued reports about the company. ValuEngine upgraded Compugen from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Oppenheimer began coverage on Compugen in a report on Thursday, March 29th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, CIBC began coverage on Compugen in a report on Thursday, March 29th. They set an “outperform” rating for the company.
Compugen (NASDAQ:CGEN) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.19) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.19). research analysts expect that Compugen will post -0.45 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of CGEN. Paloma Partners Management Co bought a new position in shares of Compugen in the fourth quarter worth about $105,000. Commonwealth Equity Services LLC bought a new position in shares of Compugen in the second quarter worth about $106,000. Jane Street Group LLC bought a new position in shares of Compugen in the fourth quarter worth about $192,000. A.R.T. Advisors LLC bought a new position in shares of Compugen in the first quarter worth about $265,000. Finally, Benjamin F. Edwards & Company Inc. increased its stake in shares of Compugen by 34.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 167,600 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 42,900 shares during the period. Institutional investors own 21.55% of the company’s stock.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.